Characteristics | Â | Number (%) | Median | Range |
---|---|---|---|---|
Sex | Â | Â | Â | Â |
 | Male | 3 (30%) |  |  |
 | Female | 7 (70%) |  |  |
Joint | Â | Â | Â | Â |
 | Wrist | 6 (55%) |  |  |
 | Knee | 3 (27%) |  |  |
 | Ankle | 2 (18%) |  |  |
Subgroup | Â | Â | Â | Â |
RF-negative polyarthritis | Â | 5 (50%) | Â | Â |
Oligoarthritis | Â | 2 (20%) | Â | Â |
Enthesitis related arthritis | Â | 1 (10%) | Â | Â |
Psoriasis arthritis | Â | 1 (10%) | Â | Â |
Systemic | Â | 1 (10%) | Â | Â |
Age, years |  |  | 14 | 11–18 |
Disease duration, years |  |  | 4.3 | 0.2–10.2 |
Drug therapies | Â | Â | Â | Â |
 | Local steroids | 1 (10%) |  |  |
 | Sulfasalazine | 1 (10%) |  |  |
 | MTX | 3 (30%) |  |  |
 | Etanercept | 1 (10%) |  |  |
 | Golimumab | 1 (10%) |  |  |
 | MTX + etanercept | 2 (20%) |  |  |
 | MTX + golimumab | 1 (10%) |  |  |